Automate Your Wheel Strategy on WGS
With Tiblio's Option Bot, you can configure your own wheel strategy including WGS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WGS
- Rev/Share 12.6776
- Book/Share 9.6968
- PB 10.9159
- Debt/Equity 0.2263
- CurrentRatio 2.8686
- ROIC 0.0081
- MktCap 3040668270.0
- FreeCF/Share 0.2033
- PFCF 523.3759
- PE 2151.6086
- Debt/Assets 0.1352
- DivYield 0
- ROE 0.0057
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WGS | Piper Sandler | -- | Overweight | -- | $110 | July 9, 2025 |
| Initiation | WGS | Guggenheim | -- | Buy | -- | $88 | May 15, 2025 |
| Upgrade | WGS | Jefferies | Hold | Buy | -- | $80 | May 9, 2025 |
| Initiation | WGS | Wells Fargo | -- | Equal Weight | -- | $34 | Aug. 28, 2024 |
News
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
GeneDx Holdings Corp. (WGS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, WGS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS)
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder litigation firm, alerts investors that it is investigating whether GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
Read More
GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a continued decline in denial rates. Momentum is building for 30%+ test volume growth in 2025, supported by testing for new indications, integration with Epic systems at hospitals, and Medicaid coverage.
Read More
GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options
Published: July 30, 2025 by: CNBC Television
Sentiment: Positive
Katherine Stueland, GeneDx CEO, joins 'Squawk Box' to discuss diagnosing children with rare diseases, cost structure of the tests, the fight against rare diseases, company growth outlook, deployment of AI, and more.
Read More
GENEDX (WGS) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options
Read More
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Sabrina Dunbar - Corporate Participant Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Gregory Brennan - TD Cowen, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Subhalaxmi T.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Read More
Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
GENEDX HOLDINGS (WGS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- News provided by DJS Law Group LLP The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws. The investigation centers on whether the Company made false and/or misleading statements or failed to disclose material information relevant to investors.
Read More
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
Read More
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Alert: Schubert Jonckheer Investigates Possible False Statements and Insider Trading
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , July 21, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis. Current shareholders are encouraged to contact the firm.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
Published: July 15, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: July 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Published: June 30, 2025 by: MarketBeat
Sentiment: Positive
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Read More
Insiders Invested Millions in these Five Rebounding Stocks
Published: June 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Marriott Vacations Worldwide director Christian Asmar bought 412,449 shares for just over $27.88 million.
Read More
GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because of superior diagnostic yield and higher cost-effectiveness if pursued earlier in the diagnostic process2. For more.
Read More
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: June 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Read More
3 Medical Services Stocks Capitalizing on the Healthcare AI Boom
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS, BTSG and WGS are three medical services stocks tapping into AI and tech-driven care to boost diagnostics, cut costs and drive growth in 2025.
Read More
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced the publication of a new article demonstrating the company's leadership in applying AI to accelerate and enhance genetic diagnostics.
Read More
Best Momentum Stocks to Buy for May 5th
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
WGS, EBMT and CBNK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2025.
Read More
About GeneDx Holdings Corp. (WGS)
- IPO Date 2020-11-04
- Website http://www.genedx.com
- Industry Medical - Healthcare Information Services
- CEO Katherine A. Stueland
- Employees 1000